ʻO ka Myeloma Nui (MM)-02

Ua ʻimi ka mea maʻi Italia i ka lāʻau lapaʻau a ua ho'ōla ʻia mai ka Multiple Myeloma me ka CAR-T Therapy

Ua ʻike ʻia ʻo Cinty, he wahine 66 makahiki, me ka lambda light chain multiple myeloma, ISS stage I, ma Italia i ʻOkakopa 2018. Ma hope o ka loaʻa ʻana o 4 mau pōʻaiapuni o ka chemotherapy VTD regimen, ua loaʻa iā ia kahi haki ma ka ʻaoʻao ʻekolu o ka clavicle a me ka peripheral neuropathy. I ka ʻimi ʻana i kahi lāʻau lapaʻau ʻoi aku ka maikaʻi, ua hana ʻia ʻo ia i ʻelua mau hoʻoili cell stem autologous i Mei 2019 a me Nowemapa 2019, me ka loaʻa ʻana o ke kala piha, a ua mālama ʻia ma ka lenalidomide waha.

Eia nō naʻe, i ʻAukake 2020, ua hōʻike kahi scan PET/CT ma hope o ka luku ʻia ʻana o ka iwi hou a me ka piʻi wikiwiki ʻana o nā kaulahao māmā serum free. Ua hōʻike ka biopsy iwi i ka holomua o ka maʻi, a ua hōʻike ka hoʻāʻo FISH i kahi ʻano cytogenetic hou: t(11;14). Ma hope o 4 mau pōʻaiapuni o ka chemotherapy DVD regimen e hoʻomaka ana i Kepakemapa 2020, ʻaʻole i kāohi ʻia kona maʻi a ua holomua hou aku. ʻOiai ua hoʻololi i 3 mau pōʻaiapuni o ka regimen PCd, ua hoʻomau ka ʻeha o kona iwi a ua ʻoi aku ka ʻino o ka edema o nā lālā haʻahaʻa bilateral. Ma hope o ka pau ʻana o nā lāʻau lapaʻau maikaʻi i ʻike ʻia ma ka honua holoʻokoʻa a ua hana ʻia ʻelua mau hoʻoili cell stem autologous, ua hoʻomohala ʻo ia i ke kūʻē ʻana i nā lāʻau lapaʻau he nui.

Ma hope o kona ʻike ʻana i ka pono koʻikoʻi o ka hoʻāʻo lapaʻau CAR-T ma kā mākou kikowaena CGT ma o ka ʻike pūnaewele, ua noi ʻo ia no kahi visa a hōʻea i Kina i Malaki 2021. Ma hope o hoʻokahi mahina o ka quarantine, ua hoʻokomo ʻia ʻo ia i kā mākou kikowaena CGT ma ʻApelila 22, 2021. Ma hope o kekahi mau hoʻokolohua a me nā loiloi maʻi, ua loaʻa iā ia kahi infusion o nā cell BCMA CAR-T ma hope o ka hoʻomaʻamaʻa mua ʻana o ka chemotherapy FC i Mei o ia makahiki. Ma hope o ka infusion, ua paʻa kāna mau hōʻailona ola, a ʻaʻohe ona hopena koʻikoʻi koe wale nō ke kuni haʻahaʻa. Ua emi mālie kona edema bilateral haʻahaʻa, a ua hauʻoli ʻo ia i ka ʻike ʻana i ka holomua o kona olakino holoʻokoʻa.

Hoʻokahi mahina ma hope o ka hoʻokomo ʻana o CAR-T, ua hōʻike nā hopena hoʻāʻo a Cinty: ka helu ʻana o ka protein mimi 24-hola ma 50 mg/lā, ua hoʻemi nui ʻia mai nā pae komo; nā kaulahao māmā serum manuahi: FLC-κ ma 4.58 mg/L a me FLC-λ ma 0.61 mg/L; a ʻaʻole i hōʻike ka loiloi ʻana o ka iwi iwi i nā cell plasma koʻikoʻi. Ua loiloi ʻia ʻo ia ma ke ʻano lapaʻau ua pau kona kala ʻana (CR).

I kēia manawa, ʻewalu mahina ma hope o kona hoʻi ʻana i Italia, ua nalowale loa ka ʻeha o ke kua o Cinty a me ka pehu o nā lālā haʻahaʻa ʻelua, a ua olakino maikaʻi ʻo ia. Mai nā tausani mile ka mamao, ua hōʻike ʻo Cinty i kona mahalo nui i kā mākou kikowaena CGT.

Hōʻike kēia mau hihia lapaʻau ʻelua mai BIOOCUS Medical Group e hiki i nā poʻe maʻi me ka haʻahaʻa a i ʻole ka ʻole o ka hōʻike ʻana o BCMA i ka myeloma maha ke hoʻokō i ka hopena maikaʻi me ka lāʻau lapaʻau BCMA CAR-T cell. Hōʻike kēia i kahi holomua i ka mālama ʻana iā CAR-T no ka myeloma maha, e lawe mai ana i ka manaʻolana hou i nā poʻe maʻi me nā maʻi cell plasma holomua a me ka myeloma maha.